Literature DB >> 20536985

HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P.

R A Ettinger1, E A James, W W Kwok, A R Thompson, K P Pratt.   

Abstract

An HLA-DRA-DRB1*0101-restricted T-cell epitope in the factor VIII (FVIII) C2 domain occurred in a mild haemophilia A patient with missense substitution FVIII-A2201P. His T cells responded to synthetic peptides FVIII(2186-2205) and FVIII(2194-2213) (J Thromb Haemost 2007; 5: 2399). T cells from family members with genotype FVIII-A2201P were analysed to determine if FVIII-specific T cells occur in individuals with a haemophilic mutation but no clinically significant inhibitor response. Fluorescent MHC class II tetramers corresponding to subjects'HLA-DRB1 types were loaded with 20-mer peptides and utilized to label antigen-specific CD4+ T cells. T-cell responses to peptides spanning the FVIII-C2 sequence were evaluated. T cells recognizing specific peptides were cloned, and antigen specificity was verified by proliferation assays. Plasma and/or purified IgG samples were tested for FVIII inhibitory activity. CD4+ T cells and T-cell clones from two brothers who shared the DRB1*0101 allele responded to FVIII(2194-2213). A haemophilic cousin's HLA-DRA-DRB1*1104-restricted response to FVIII(2202-2221) was detected only when CD4+CD25+ cells were depleted. A great uncle and two obligate carriers had no detectable FVIII-C2-specific T cells. Concentrated IgG from the brother without a clinical inhibitor response showed a low-titre FVIII inhibitor. FVIII-specific T cells and inhibitory IgG were found in a previously infused, haemophilic subject who had a sub-clinical FVIII inhibitor. CD4+CD25+ depleted T cells from a non-infused haemophilic cousin recognized an overlapping FVIII epitope, indicating a latent HLA-DRA-DRB1*1104-restricted T-cell response to FVIII. Specific T-cell responses to FVIII can occur without clinically significant inhibitors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20536985      PMCID: PMC2885051          DOI: 10.1111/j.1365-2516.2008.01905.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  58 in total

Review 1.  Risk factors for inhibitor development in hemophilia A.

Authors:  J Oldenburg; H H Brackmann; R Schwaab
Journal:  Haematologica       Date:  2000-10       Impact factor: 9.941

2.  Tetramer-guided epitope mapping: rapid identification and characterization of immunodominant CD4+ T cell epitopes from complex antigens.

Authors:  E J Novak; A W Liu; J A Gebe; B A Falk; G T Nepom; D M Koelle; W W Kwok
Journal:  J Immunol       Date:  2001-06-01       Impact factor: 5.422

3.  Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes.

Authors:  E N van Den Brink; E A Turenhout; J Davies; N Bovenschen; K Fijnvandraat; W H Ouwehand; M Peters; J Voorberg
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

4.  Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects.

Authors:  M T Reding; H Wu; M Krampf; D K Okita; B M Diethelm-Okita; B A Christie; N S Key; B M Conti-Fine
Journal:  Thromb Haemost       Date:  2000-10       Impact factor: 5.249

5.  In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.

Authors:  D H Scandella; H Nakai; M Felch; W Mondorf; I Scharrer; L W Hoyer; E L Saenko
Journal:  Thromb Res       Date:  2001-03-01       Impact factor: 3.944

6.  Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure.

Authors:  M L Liu; B W Shen; S Nakaya; K P Pratt; K Fujikawa; E W Davie; B L Stoddard; A R Thompson
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

7.  Malmö International Brother Study (MIBS): an international survey of brother pairs with haemophilia.

Authors:  J Astermark; E Berntorp
Journal:  Vox Sang       Date:  1999       Impact factor: 2.144

8.  The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients.

Authors:  J Astermark; E Berntorp; G C White; B L Kroner
Journal:  Haemophilia       Date:  2001-05       Impact factor: 4.287

9.  Non-inversion factor VIII mutations in 80 hemophilia A families including 24 with alloimmune responses.

Authors:  Miao-Liang Liu; Shelley Nakaya; Arthur R Thompson
Journal:  Thromb Haemost       Date:  2002-02       Impact factor: 5.249

10.  T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide.

Authors:  E A James; W W Kwok; R A Ettinger; A R Thompson; K P Pratt
Journal:  J Thromb Haemost       Date:  2007-12       Impact factor: 5.824

View more
  28 in total

1.  Avidity of human T cell receptor engineered CD4(+) T cells drives T-helper differentiation fate.

Authors:  Patrick Adair; Yong Chan Kim; Kathleen P Pratt; David W Scott
Journal:  Cell Immunol       Date:  2015-10-23       Impact factor: 4.868

Review 2.  Inhibitors - cellular aspects and novel approaches for tolerance.

Authors:  D W Scott
Journal:  Haemophilia       Date:  2014-05       Impact factor: 4.287

3.  Factor VIII gene variants and inhibitor risk in African American hemophilia A patients.

Authors:  Devi Gunasekera; Ruth A Ettinger; Shelley Nakaya Fletcher; Eddie A James; Maochang Liu; John C Barrett; Janice Withycombe; Dana C Matthews; Melinda S Epstein; Richard J Hughes; Kathleen P Pratt
Journal:  Blood       Date:  2015-01-23       Impact factor: 22.113

4.  T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire.

Authors:  Ruth A Ettinger; Pedro Paz; Eddie A James; Devi Gunasekera; Fred Aswad; Arthur R Thompson; Dana C Matthews; Kathleen P Pratt
Journal:  Blood       Date:  2016-07-28       Impact factor: 22.113

5.  CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells.

Authors:  Sylvain Meunier; Catherine Menier; Elodie Marcon; Sébastien Lacroix-Desmazes; Bernard Maillère
Journal:  Blood Adv       Date:  2017-09-25

6.  Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice.

Authors:  Weiqing Jing; Juan Chen; Yuanhua Cai; Yingyu Chen; Jocelyn A Schroeder; Bryon D Johnson; Weiguo Cui; Qizhen Shi
Journal:  Blood Adv       Date:  2019-10-22

Review 7.  Haemophilia management: time to get personal?

Authors:  T E Howard; C Yanover; J Mahlangu; A Krause; K R Viel; C K Kasper; K P Pratt
Journal:  Haemophilia       Date:  2011-06-08       Impact factor: 4.287

8.  FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity.

Authors:  Ruth A Ettinger; Joseph A Liberman; Devi Gunasekera; Komal Puranik; Eddie A James; Arthur R Thompson; Kathleen P Pratt
Journal:  Blood Adv       Date:  2018-02-27

9.  Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.

Authors:  Yong Chan Kim; Ai-Hong Zhang; Yan Su; Sadiye Amcaoglu Rieder; Robert J Rossi; Ruth A Ettinger; Kathleen P Pratt; Ethan M Shevach; David W Scott
Journal:  Blood       Date:  2014-12-10       Impact factor: 22.113

Review 10.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.